Helixor M (Liquid Extract From Viscum Album Subsp. Album Var Malus Domestica (1:20), Extraction Solvents: Water)

Helixor M is employed in complementary oncology practice, where it is administered as part of individualized treatment protocols.

• Adjunctive therapy in patients with solid tumors.
• Supportive care for individuals undergoing conventional cancer treatments.
• Investigational use in clinical studies evaluating immunomodulatory effects.
• Potential application in symptom management such as fatigue or quality‑of‑life measures.
• Use in combination with standard chemotherapy regimens under physician oversight.
• Exploration of effects on tumor‑associated immune cell populations in research settings.

Reported adverse reactions to Helixor M are generally mild, but rare serious events have been documented in post‑marketing surveillance.

Common

• Local injection site reactions such as redness, mild swelling, or bruising that resolve within a few days.
• Transient fever, chills, or flu‑like symptoms occurring within 24‑48 hours after administration.
• Temporary fatigue, mild headache, or dizziness that are self‑limiting.
• Slight, asymptomatic elevations in liver enzymes detected on routine laboratory testing.

Serious

• Severe allergic reactions, including urticaria, angioedema, or anaphylaxis requiring emergency treatment.
• Significant hypotension or circulatory collapse occurring shortly after injection.
• Autoimmune‑mediated organ inflammation such as hepatitis, colitis, or pneumonitis reported in isolated cases.

Helixor M should be prescribed and administered only after a thorough clinical assessment, taking into account patient‑specific factors and potential risks.

• Verify absence of known hypersensitivity to mistletoe extracts before initiating therapy.
• Conduct baseline laboratory tests, including complete blood count and liver function, and monitor periodically.
• Use caution in patients with autoimmune disorders or a history of severe allergic reactions.
• Avoid administration in individuals with uncontrolled cardiovascular disease or active infections.
• Adjust or discontinue use if significant laboratory abnormalities or adverse reactions develop.
• Ensure proper aseptic technique during subcutaneous injection to prevent local infection.

Helixor M may interact with other medicines or biologic agents; known or theoretical interactions should be reviewed before co‑administration.

Avoid

• Concurrent use with other immunomodulatory botanical preparations without medical supervision.
• Simultaneous administration with high‑dose corticosteroids that may blunt immunologic effects.
• Do not combine with other mistletoe‑based products, as cumulative dosing is undefined.

Use with caution

• Combination with chemotherapy agents; monitor for additive toxicity or altered efficacy.
• Use alongside anticoagulants; observe for unexpected bleeding or bruising at injection sites.
• Co‑administration with biologic immune‑checkpoint inhibitors should be monitored for synergistic immune activation.
• Concomitant use with vaccines; assess timing to avoid potential interference with immune response.